Influence of N-methyl-N-nitrosourea, testosterone, and N-(4- hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar- Unilever rats

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3282-3288

  McCormick, David L ^a   Rao, K V N ^a   Dooley, Lawrence ^a   Steele, Vernon E ^b   Lubet, Ronald A ^b   Kelloff, Gary J ^b   Bosland, Maarten C ^c  

^a IIT RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; METHYLNITROSOUREA; TESTOSTERONE;

ACCESSORY SEX GLAND; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DIET; HORMONAL CARCINOGENESIS; HORMONAL REGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SEMINAL VESICLE;

ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; CARCINOGENS; COCARCINOGENESIS; FENRETINIDE; MALE; METHYLNITROSOUREA; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; TESTOSTERONE;

EID: 0032146326     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 65: 5-27, 1996.
2. Chiarodo, A. National Cancer Institute roundtable on prostate cancer: future research directions. Cancer Res., 51: 2498-2505, 1991.
3. Bosland, M. C., and Prinsen, M. K. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz(a)anthracene, and 3,2′-dimethyl-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res., 50: 691-699, 1990.
4. Bosland, M. C., Prinsen, M. K., Dirksen, T. J. M., and Spit, B. J. Characterization of adeno-carcinomas of the dorsolateral prostate induced in Wistar rats by N-methyl-N-nitrosourea 7,12-dimethylbenz(a)anthracene, and 3,2′-dimethyl-4-aminobiphenyl, following sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res., 50: 700-709, 1990.
5. Moon, R. C., Thompson, H. J., Becci, P. J., Grubbs, C. J., Gander, R. L., Newton, D. L., Smith, J. M., Phillips, S. L., Henderson, W. R., Mullen, L. T., Brown, C. C., and Sporn, M. B. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res., 39: 1339-1346, 1979.
6. Moon, R. C., McCormick, D. L., Becci, P. J., Shealy, Y. F., Frickel, F., Paust, J., and Sporn, M. B. Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. Carcinogenesis (Lond.), 3: 1469-1472, 1982.
7. Welsch, C. W., DeHoog, J. V., and Moon, R. C. Inhibition of mammary tumorigenesis in nulliparous C3H mice by chronic feeding of the synthetic retinoid, N-(4-hydroxyphenyl)-retinamide. Carcinogenesis (Lond.), 4: 1185-1187, 1983.
8. McCormick, D. L., and Moon, R. C. Antipromotional activity of N-(4-hydroxyphenyl)retina-mide in two-stage tumorigenesis in CD-1 and SENCAR rruce. Cancer Lett., 31: 133-138, 1986.
9. McCormick, D. L., Johnson, W. D., Rao, K. V. N., Bowman-Gram, T., Steele, V. E., Lubet, R. A., and Kelloff, G. J. Comparative activity of N-(4-hydroxyphenyl)-all-trans-retinamide and α-difluoromethylomithine as inhibitors of lymphoma induction in PIM transgenic mice. Carcinogenesis (Lond.), 17: 2513-2517, 1996.
10. Bosland, M. C., Dreef-Van Der Meulen, H. C., Sukumar, S., Ofner, P., Leav, I., Han, X., and Liehr, J. G. Multistage prostate carcinogenesis: the role of hormones. In: C. C. Harris, S. Hirohashi, N. Ito, H. C. Pito, T. Sugimura, M. Terada, and J. Yokota, J. (eds.) Multistage Carcinogenesis, pp. 109-123. Boca Raton, FL: CRC Press, 1992.
11. Ohshima, M., Ward, J. M., and Wenk, M. L. Preventive and enhancing effects of retinoids on the development of naturally occurring tumors of skin, prostate gland, and endocrine pancreas in aged male ACI/segHapBR rats. J. Natl. Cancer Inst., 74: 517-524, 1985.
12. Hultin, T. A., McCormick, D. L., May, C. M., and Moon, R. C. Effects of pretreatment with the retinoid N-(4-hydroxyphenyl)-all-trans-retinamide and phenobarbital on the disposition and metabolism of N-(4-hydroxyphenyl)-all-trans-retinamide in mice. Drug. Metab. Dispos., 16: 783-788, 1988.
13. Bosland, M. C. Animal models for the study of prostatic carcinogenesis. J. Cell. Biochem. Suppl., 16H: 89-98, 1992.
14. Bosland, M. C. Age-related lesions in the male accessory sex glands and penis of the rat. In: U. Mohr et al., (eds.), Monographs on Pathology of the Aging Rat, Vol. 1, pp. 443-467. Washington, DC: ILSI Press, 1992.
15. Sakr, W. A., Haas, G. P., Cassin, B. F., Pontes, J. E., and Crissman, J. D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol., 150: 379-385, 1993.
16. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
17. Benson, R. C., Jr., Clark, W. R., and Farrow, G. M. Carcinoma of the seminal vesicle. J. Urol., 132: 483-485, 1984.
18. Slayter, M. V., Anzano, M. A., Kadomatsu, K., Smith, J. M., and Sporn, M. B. Histogenesis of induced prostate and seminal vesicle carcinoma in Lobund-Wistar rats: a system for histological scoring and grading. Cancer Res., 54: 1440-1445, 1994.
19. Lucia, M. S., Anzano, M. A., Slayter, M. V., Anver, M. R., Green, D. M., Shrader, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Peer, C. W., Roberts, A. B., and Sporn, M. B. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)-retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res., 55: 5621-5627, 1995.
20. Price, D. Comparative aspects of development and structure in the prostate. Natl. Cancer Inst. Monogr., 12: 1-27, 1963.
21. Pollard, M., Luckert, P. H., and Sporn, M. B. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res., 51: 3610-3611, 1991.
22. Cohen, M. B., Heidger, P. M., and Lubaroff, D. M. Gross and microscopic pathology of induced prostatic complex tumors arising in Lobund-Wistar rats. Cancer Res., 54: 626-628, 1994.
23. Tamano, S., Rehm, S., Waalkes, M. P., and Ward, J. M. High incidence and histogenesis of seminal vesicle adenocarcinoma and lower incidence of prostate carcinomas in the Lobund-Wistar prostate cancer rat model using N-nitrosomethylurea and testosterone. Vet. Pathol., 33: 557-567, 1996.
24. Shain, S. A., McCullough, B., Nitchuk, M., and Boesel, R. W. Prostate carcinogenesis in the AXC rat. Oncology, 34: 114-122, 1977.
25. Ward, J. M., Reznik, G., Stinson, S. F., Lattuada, C. P., Longfellow, D. G., and Cameron, T. P. Histogenesis and morphology of naturally occurring prostatic carcinoma in the ACI/segHapBR rat. Lab. Invest., 43: 517-522, 1980.
26. Slawin, K., Kadmon, D., Park, S. H., Scardino, P. T., Anzano, M., Sporn, M. B., and Thompson, T. C. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res., 53: 4461-4465, 1993.
27. Pienta, K. J., Nguyen, N. M., and Lehr, J. E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res., 53: 224-226, 1993.